Complement Inhibition in Geographic Atrophy: Slowing Progression With Novel Treatments (June 22 CE Webinar)
This educational activity is intended for optometrists.
After completing this activity, participants will be better able to:
- Recognize epidemiologic indicators of patients who may be at higher risk for geographic atrophy
- Describe the pathophysiology of geographic atrophy as it relates to disease management
- Identify the features of geographic atrophy on imaging
- Review clinical trial data for therapy that targets complement for geographic atrophy
- Incorporate education on geographic atrophy regularly into patient encounters
Steven Ferrucci, OD
Arshad M. Khanani, MD, MA
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.
Steven Ferrucci, OD, is an advisory board member of Iveric Bio, Inc, Novartis Pharmaceuticals Corporation, ScienceBased Health, and Visible Genomics; and is on the speakers bureau for Apellis Pharmaceuticals, LKC Technologies, Inc, Icare USA Inc, Regeneron Pharmaceuticals, Inc*, and Visionix.
Arshad M. Khanani, MD, MA, is a consultant for AbbVie Inc, Adverum, Aerie Pharmaceuticals, Inc, AGTC, Aldebaran Therapeutics, Apellis Pharmaceuticals, Arrowhead Pharmaceuticals, Inc, Aviceda Therapeutics, Bausch & Lomb Incorporated, Broadwing Bio, Clearside Biomedical, Inc, Exegenesis Bio, EyePoint Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, 4DMT, Frontera Therapeutics, Inc, Genentech, Inc, Gyroscope, i-Lumen Scientific, Iveric Bio, Inc, Janssen Pharmaceuticals, Inc, Kato Pharmaceuticals, Kodiak Sciences Inc, Nanoscope Therapeutics, Notal Vision, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oculis, Ocuterra, Olives Bio, Opthea, Oxurion NV, Perfuse Therapeutics, PolyPhotonix, Protagonist Therapeutics Inc, Ray Therapeutics, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Stealth BioTherapeutics Inc, Thea Pharmaceuticals Limited, Unity Biotechnology, Vanotech, and Vial; and is a contracted researcher for Adverum, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, 4DMT, Genentech, Inc, Gyroscope, Iveric Bio, Inc, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oculis, Ocuterra, Opthea, Oxurion NV, and Recens Medical, Inc.
* The financial relationship existed during the last 24 months but has now ended
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 84660-TD
COPE Course Category: Treatment & Management of Ocular Disease
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Iveric Bio, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Iveric Bio, Inc.
©2023 MedEdicus LLC. 296.3c
- 1.00 COPE